Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 5/20 | 0.48 |
| ▸ | MAOB | P27338 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20439319 | 1.00 | SCN4A (0.48) | SCN4AMAOBSMN1; SMN2KMT2AGAA | |
| SCHEMBL20439314 | 0.94 | SCN4A (0.43) | SCN4AMAOBSMN1; SMN2KMT2AGAA | |
| SCHEMBL20439307 | 0.93 | MAOB (0.44) | SCN4AMAOBSMN1; SMN2KMT2AMAOA | |
| SCHEMBL20439308 | 0.93 | MAOB (0.44) | SCN4AMAOBSMN1; SMN2KMT2AMAOA | |
| SCHEMBL20439378 | 0.85 | KMT2A (0.40) | MAOBSMN1; SMN2KMT2AMAPTL3MBTL1 | |
| SCHEMBL20439375 | 0.82 | DHFR (0.37) | MAOBSMN1; SMN2KMT2AMAOARAB9A | |
| SCHEMBL20439360 | 0.82 | DHFR (0.37) | MAOBSMN1; SMN2KMT2AMAOARAB9A | |
| SCHEMBL615020 | 0.82 | MAOB (0.59) | MAOBSMN1; SMN2GAAMAPTMAOA | |
| SCHEMBL30628889 | 0.82 | MAOB (0.59) | MAOBSMN1; SMN2GAAMAPTMAOA | |
| SCHEMBL14569807 | 0.79 | SLC2A1 (0.51) | SCN4ASMN1; SMN2CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018138739-A1 | NOVEL ANTIESTROGENIC HETEROCYCLIC COMPOUNDS | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2018-08-02 | — | — | WO | disclosed |
| US-7196081-B2 | Compounds with hydroxycarbonyl-halogenoalkyl side chains | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-03-27 | — | — | US | disclosed |
| US-20050192449-A1 | Compounds with hydroxycarbonyl-halogenoalkyl side chains | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-09-01 | — | — | US | disclosed |
| US-6737417-B2 | AN ANTIESTROGENIC AGENT CONTAININING AROMATIC OR HETEROAROMATIC COMPOUNDS CONTAINING HYDROXYCARBONYL OR METAL SALT- HALOGENOALKYL SIDE CHAIN; USEFUL FOR TREATING BREAST CANCER | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-05-18 | — | — | US | disclosed |
| EP-1361205-A1 | Compounds with hydroxycarbonyl-halogenalkyl side chains | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-11-12 | — | — | EP | disclosed |
| US-20030130347-A1 | Compounds with hydroxycarbonyl-halogenoalkyl side chains | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-07-10 | — | — | US | disclosed |
| US-20030114524-A1 | Compounds with hydroxycarbonyl-halogenoalkyl side chain | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-06-19 | — | — | US | disclosed |
| EP-1241158-A1 | COMPOUND HAVING HYDROXYCARBONYL-HALOGENOALKYL SIDE CHAIN | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192449-A1 | Compounds with hydroxycarbonyl-halogenoalkyl side chains | CYP19A1, HSD17B11, SHBG | SCN4A 2188/4885MAOB 3226/4885SMN1; SMN2 4603/4885 |
| US-20030114524-A1 | Compounds with hydroxycarbonyl-halogenoalkyl side chain | HSD17B11, CYP19A1, SHBG | SCN4A 1972/4885MAOB 3704/4885SMN1; SMN2 4678/4885 |
| US-20030130347-A1 | Compounds with hydroxycarbonyl-halogenoalkyl side chains | HSD17B11, CYP19A1, SHBG | SCN4A 2016/4885MAOB 3740/4885SMN1; SMN2 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.